Síndrome de larón e inmunidad al cáncer y la diabetes
Palabras clave:
Enanismo, - IGF-1 – Diabetes– Hormona GH – Cáncer.Resumen
El Síndrome de Laron o Enanismo tipo Laron, también llamado Insensibilidad a la Hormona del Crecimiento (IGH), es una enfermedad rara, congénita, autosómica recesiva que no presenta diferencias de afectación por el sexo. Se han descrito un aproximado de 350 casos de la enfermedad a nivel mundial, sobre todo en el mediterráneo (Israel, Arabia Saudita, Egipto e Irak) y con mayor incidencia en Ecuador, específicamente en las provincias de Loja y El Oro, donde se encuentra el 75% del total de casos descritos en el mundo. El objetivo de la presente investigación es documentar las bases genéticas implicadas en la fisiopatología y desarrollo de la enfermedad, así como su asociación a cáncer y diabetes mellitus en la población ecuatoriana. El marco metodológico incluye un diseño documental, mediante una búsqueda bibliográfica sistemática de artículos a texto completo, publicados hasta diciembre de 2021, en revistas indexadas en las bases de datos científicas y buscadores PubMed, MEDLINE, Cochrane, Google Scholar, SciELO, Scopus, Redalyc, Elsevier y WOS. Se espera evidenciar las características genotípicas y fenotípicas más relevantes en la población ecuatoriana, así como las posibles teorías en la fisiopatología y su asociación a un menor riesgo a generar diabetes mellitus y cáncer.
Descargas
Citas
Chesnokova V. The Multiple Faces of the GH/IGF Axis. Cells. 2022;11(2):217. doi: 10.3390/cells11020217. PMID: 35053333; PMCID: PMC8773948.
Ramírez López LR, Vinueza López DE, Jácome Sánchez MF, Viteri Rodríguez JA. Enanismo tipo Laron, el síndrome con incidencia disminuida en diabetes y cáncer: revisión bibliográfica. Universidad y Sociedad. 2022;13(6):548-54. Disponible en: https://rus.ucf.edu.cu/index.php/rus/article/view/2420
Kopchick JJ. Lessons learned from studies with the growth hormone receptor. Growth Horm IGF Res. 2016; 28:21-25. doi: 10.1016/j.ghir.2015.06.003PMID: 26216709.
Grimberg A, Di Vall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH. Guidelines for growth hormone and insulin-like growth Factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Hormone Research in Paediatrics. 2016; 86(6), 361-397.
Storr HL, Dunkel L, Kowalczyk J, Savage MO, Metherell LA. Genetic characterization of a cohort of children clinically labelled as GH or IGF1 insensitive: diagnostic value of serum IGF1 and height at presentation. Eur J Endocrinol. 2015;172(2):151-61. doi: 10.1530/EJE-14-0541. PMID: 25411237.
Laron Z. Epilogue: The future of Laron syndrome - The need for changes. Growth Horm IGF Res. 2016; 28:79-80. doi: 10.1016/j.ghir.2015.07.007. PMID: 26283274.
Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016; 14:3. doi: 10.1186/s12967-015-0762-z. PMID: 26733412; PMCID: PMC4702316.
Werner H, Lapkina-Gendler L, Achlaug L, Nagaraj K, Somri L, Yaron-Saminsky D, Pasmanik-Chor M, Sarfstein R, Laron Z, Yakar S. Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways. Cells. 2019;8(6):596. doi: 10.3390/celSL8060596. PMID: 31208077; PMCID: PMC6627189.
Ministerio de Salud Pública de Ecuador. Informe trimestral de atención a pacientes con diagnóstico presuntivo o confirmatorio de Síndrome de Laron. Abril-junio 2020. Disponible en: http://esacc.corteconstitucional.gob.ec/storage/api/v1/10_DWL_FL/e2NhcnBldGE6J2VzY3JpdG8nLCB1dWlkOidkOTFmMDY1MS04NjMwLTRkNjYtYjFiZi1kNTA2NzhlZTZlOWQucGRmJ30=
Castilla-Cortazar I, De Ita JR, García-Magariño M, Aguirre GA, Castorena-Torres F, Valdez-Garcia JE, Ortiz-Urbina J, de la Garza RG, Fraustro-Avila E, Rodríguez-Zambrano MA, Elizondo MI. A 42-Year-Old Woman with Untreated Growth Hormone Insensitivity, Diabetic Retinopathy, and Gene Sequencing Identifies a Variant of Laron Syndrome. Am J Case Rep. 2019; 20:689-696. doi: 10.12659/AJCR.913178. PMID: 31086127; PMCID: PMC6530522.
Laron Z. Lessons from 50 years of study of Laron Syndrome. Endocr Pract. 2015; 21(12):1395-402. doi: 10.4158/EP15939.RA. PMID: 26401581.
Laron Z, Werner H. Laron syndrome - A historical perspective. Rev Endocr Metab Disord. 2021; 22(1):31-41. doi: 10.1007/s11154-020-09595-0. PMID: 32964395.
Janecka A, Kołodziej-Rzepa M, Biesaga B. Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer. In Vivo. 2016;30(4):375–381.Disponible en: http://iv.iiarjournaSL.org/content/30/4/375.long
Li R, Gong F, Pan H, Liang H, Miao H, Zhao Y, Duan L, Yang H, Wang L, Chen S, Zhu H. Identification and in vitro functional verification of two novel mutations of GHR Gene in the Chinese children with Laron Syndrome. Front Endocrinol (Lausanne). 2021; 12:605736. doi: 10.3389/fendo.2021.605736. PMID: 33912130; PMCID: PMC8072467.
Werner H, Sarfstein R, Nagaraj K, Laron Z. Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation. Cells. 2020; 9(11):2446. doi: 10.3390/celSL9112446. PMID: 33182502; PMCID: PMC7696416.
Barazani C, Werner H, Laron Z. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - A pilot study. Growth Horm IGF Res. 2020; 52:101312. doi: 10.1016/j.ghir.2020.02.001. Epub 2020 Feb 11. PMID: 32200226.
Guevara-Aguirre J, Bautista C, Torres C, Peña G, Guevara C, Palacios C, Guevara A, Gavilanes AWD. Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador. Rev Endocr Metab Disord. 2021; 22(1):59-70. doi: 10.1007/s11154-020-09602-4. PMID: 33047268.
Rosenbloom AL. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective. Growth Horm IGF Res. 2016; 28:46-50. doi: 10.1016/j.ghir.2015.08.001. PMID: 26276451.
Moia S, Tessaris D, Einaudi S, de Sanctis L, Bona G, Bellone S, Prodam F. Compound heterozygosity for two GHR missense mutations in a patient affected by Laron Syndrome: a case report. Ital J Pediatr. 2017; 43(1):94. doi: 10.1186/s13052-017-0411-7. PMID: 29025428; PMCID: PMC5639735.
Akinci A, Karakurt C, Hwa V, Dündar I, Çamtosun E. Laron syndrome related to homozygous growth hormone receptor c.784>C mutation in a patient with hypoplastic pulmonary arteries. Cardiovasc J Afr. 2019;30(2):e7-e8. doi: 10.5830/CVJA-2019-002. PMID: 30720842.
Villela TR, Freire BL, Braga NTP, Arantes RR, Funari MFA, Alexander JAL, Silva IN. Growth Hormone insensitivity (Laron syndrome): Report of a new family and review of Brazilian patients. Genet Mol Biol. 2020;42(4):e20180197. doi: 10.1590/1678-4685-GMB-2018-0197. PMID: 31429861; PMCID: PMC7197995.
Cannarella R, Crafa A, La Vignera S, Condorelli RA, Calogero AE. Role of the GH-IGF1 axis on the hypothalamus-pituitary-testicular axis function: lessons from Laron syndrome. Endocr Connect. 2021 Aug 25;10(9):1006-1017. doi: 10.1530/EC-21-0252. PMID: 34319907; PMCID: PMC8428041.
Chreitah A, Hijazia K, Doya LJ. Laron syndrome in three female siblings with the development of subclinical hypothyroidism and dyslipidemia in one case: first report of a Syrian family. Oxf Med Case Reports. 2021 Sep 13;2021(9):omab079. doi: 10.1093/omcr/omab079. PMID: 34527252; PMCID: PMC8436272.
Goldberg L, Laron Z, Kornreich L, Scheuerman O, Goldberg-Stern H, Kraus D. Focal epilepsy in Individuals with Laron syndrome. Horm Res Paediatr. 2022 Mar 31. doi: 10.1159/000524350. PMID: 35358968.
Rosenbloom AL, Guevara-Aguirre J. Growth Hormone Resistance. Medscape. 2015. Disponible en: http://emedicine.medscape.com/article/922902-.
Domené HM, Fierro-Carrión G. Genetic disorders of GH action pathway. Growth Horm IGF Res. 2018; 38:19-23. doi: 10.1016/j.ghir.2017.12.004. PMID: 29249625.
Guevara-Aguirre J, Rosenbloom AL. Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency. Diabetologia. 2015 Jan;58(1):37-42. doi: 10.1007/s00125-014-3397-3. PMID: 25316432.
Guevara Aguirre J, Rosenbloom AL, Balasubramaniam P, Teran E, Guevara Aguirre M, Guevara C,Procel P, Alfaras I, De Cabo R, Di Biase S, Narvaez L, Saavedra, J, Longo VD. Absent GH counterregulation due to GH receptor deficiency with obesity and enhanced insulin sensitivity.J Clin Endocrinol Metab. 2015; 100:2589-2596.
Addo OY, Sarafoglou K, Miller BS. Effect of Adjusting for Tanner Stage Age on Prevalence of Short and Tall Stature of Youths in the United States. J Pediatr. 2018; 201:93-99.e4. doi: 10.1016/j.jpeds.2018.05.051. PMID: 30005924.
Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Horm Res Paediatr. 2019;92(1):1-14. doi: 10.1159/000502231. PMID: 31514194; PMCID: PMC6979443.
Abad-García MF. El plagio y las revistas depredadoras como amenaza a la integridad científica. Anales de Pediatría. 2019; Volume 90 (1):57.e1-57.e8J2021; 57:21-34. Doi: https://doi.org/10.1016/j.anpedi.2018.11.003
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
Guevara-Aguirre J, Rosenbloom AL, Balasubramanian P, Teran E, Guevara-Aguirre M, Guevara C, Procel P, Alfaras I, De Cabo R, Di Biase S, Narvaez L, Saavedra J, Longo VD. GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity. J Clin Endocrinol Metab. 2015;100(7):2589-96. doi: 10.1210/jc.2015-1678. PMID: 25985182; PMCID: PMC4490304.
Laron Z, Kauli R. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment. Growth Horm IGF Res. 2016; 28:53-6. doi: 10.1016/j.ghir.2015.08.004. PMID: 26307357.
Castilla-Cortazar I, Femat-Roldán G, Rodríguez-Rivera J, Aguirre GA, García-Magariño M, Martín-Estal I, Espinosa L, Díaz-Olachea C. Mexican case report of a never-treated Laron syndrome patient evolving to metabolic syndrome, type 2 diabetes, and stroke. Clin Case Rep. 2017; 5(11):1852-1855. doi: 10.1002/ccr3.1193. PMID: 29152285; PMCID: PMC5676289.
Castilla-Cortazar I, de Ita JR, Aguirre GA, Castorena-Torres F, Ortiz-Urbina J, García-Magariño M, de la Garza RG, Diaz Olachea C, Elizondo Leal MI. Fanconi Anemia and Laron Syndrome. Am J Med Sci. 2017; 353(5):425-432. doi: 10.1016/j.amjms.2017.02.001. PMID: 28502327.
Guevara-Aguirre J, Bautista C, Torres C, Peña G, Guevara C, Palacios C, Guevara A, Gavilanes AWD. Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador. Rev Endocr Metab Disord. 2021; 22(1):59-70. doi: 10.1007/s11154-020-09602-4. PMID: 33047268.
Boro H, Hammadur Rahman Sk, Khatiwada S, Alam S, Khadgawat R. Laron syndrome: An experience of treatment of two cases. Journal of Clinical and Translational Endocrinology: Case Reports. 2021; Volume 19, https://doi.org/10.1016/j.jecr.2020.100076.
Tarantini S, Tucsek Z, Valcarcel-Ares MN, Toth P, Gautam T, Giles CB, Ballabh P, Wei JY, Wren JD, Ashpole NM, Sonntag WE, Ungvari Z, Csiszar A. Circulating IGF-1 deficiency exacerbates hypertension-induced microvascular rarefaction in the mouse hippocampus and retrosplenial cortex: implications for cerebromicrovascular and brain aging. Age (Dordr). 2016; 38(4):273-289. doi: 10.1007/s11357-016-9931-0. PMID: 27613724; PMCID: PMC5061685.
Guevara-Aguirre J, Teran E, Lescano D, Guevara C, Guevara A, Saavedra J, Procel P, Wasserfall C, Gavilanes AWD. Assessing insulin sensitivity and resistance in syndromes of severe short stature. Growth Horm IGF Res. 2020;53-54:101339. doi: 10.1016/j.ghir.2020.101339. PMID: 32763832.
Hinrichs A, Renner S, Bidlingmaier M, Kopchick JJ, Wolf E. Mechanisms in endocrinology: Transient juvenile hypoglycemia in growth hormone receptor deficiency - mechanistic insights from Laron syndrome and tailored animal models. Eur J Endocrinol. 2021;185(2):R35-R47. doi: 10.1530/EJE-21-0013. PMID: 34048365.
Laron Z, Kauli R, Lapkina L, Werner H. IGF-I deficiency, longevity and cancer protection of patients with Laron síndrome. Mutation Research/Reviews in Mutation Research. 2017; Vol 772: 123-133. https://doi.org/10.1016/j.mrrev.2016.08.002.
Podlutsky A, Valcarcel-Ares MN, Yancey K, Podlutskaya V, Nagykaldi E, Gautam T, Miller RA, Sonntag WE, Csiszar A, Ungvari Z. The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer. Geroscience. 2017;39(2):147-160. doi: 10.1007/s11357-017-9966-x. PMID: 28233247; PMCID: PMC5411369.
Nagaraj K, Lapkina-Gendler L, Sarfstein R, Gurwitz D, Pasmanik-Chor M, Laron Z, Yakar S, Werner H. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. Proc Natl Acad Sci U S A. 2018;115(5):1045-1050. doi: 10.1073/pnas.1715930115. PMID: 29339473; PMCID: PMC5798358.
Achlaug L, Sarfstein R, Nagaraj K, Lapkina-Gendler L, Bruchim I, Dixit M, Laron Z, Yakar S, Werner H. Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer. Oncotarget. 2019;10(43):4437-4448. doi: 10.18632/oncotarget.27055. PMID: 31320996; PMCID: PMC6633887.
Aguiar-Oliveira MH, Bartke A. Growth Hormone Deficiency: Health and Longevity. Endocr Rev. 2019;40(2):575-601. doi: 10.1210/er.2018-00216. PMID: 30576428; PMCID: PMC6416709.
Sarfstein R, Lapkina-Gendler L, Nagaraj K, Laron Z, Werner H. Identification of nephronectin as a new target for IGF1 action. Eur J Cancer. 2020; 141:115-127. doi: 10.1016/j.ejca.2020.09.034. Erratum in: Eur J Cancer. 2021 May;148:453-454. PMID: 33130549.
Yaron-Saminsky D, Nagaraj K, Sarfstein R, Laron Z, Pasmanik-Chor M, Werner H. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression. Int J Mol Sci. 2021;22(21):11861. doi: 10.3390/ijms222111861. PMID: 34769292; PMCID: PMC8584665.
Shibel R, Sarfstein R, Nagaraj K, Lapkina-Gendler L, Laron Z, Dixit M, Yakar S, Werner H. The Olfactory Receptor Gene Product, OR5H2, Modulates Endometrial Cancer Cells Proliferation via Interaction with the IGF1 Signaling Pathway. Cells. 2021;10(6):1483. doi: 10.3390/cells10061483. PMID: 34204736; PMCID: PMC8231575.
Kopchick JJ, Basu R, Berryman DE, Jorgensen JOL, Johannsson G, Puri V. Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Nat Rev Endocrinol. 2022. doi: 10.1038/s41574-022-00702-6. PMID: 35750929.
Guevara-Aguirre J, Guevara A, Bahamonde M. Insulin resistance depends on GH counter-regulation in two syndromes of short stature. Growth Horm IGF Res. 2018; 38:44-48. doi: 10.1016/j.ghir.2017.12.012. PMID: 29306561.
Guevara-Aguirre J, Procel P, Guevara C, Guevara-Aguirre M, Rosado V, Teran E. Despite higher body fat content, Ecuadorian subjects with Laron syndrome have less insulin resistance and lower incidence of diabetes than their relatives. Growth Horm IGF Res. 2016; 28:76-8. doi: 10.1016/j.ghir.2015.08.002. PMID: 26259979.
Guevara-Aguirre J, Guevara A, Palacios I, Pérez M, Prócel P, Terán E. GH and GHR signaling in human disease. Growth Horm IGF Res. 2018; 38:34-38. doi: 10.1016/j.ghir.2017.12.006. PMID: 29395968.
Hinrichs A, Kessler B, Kurome M, Blutke A, Kemter E, Bernau M, Scholz AM, Rathkolb B, Renner S, Bultmann S, Leonhardt H, de Angelis MH, Nagashima H, Hoeflich A, Blum WF, Bidlingmaier M, Wanke R, Dahlhoff M, Wolf E. Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver. Mol Metab. 2018; 11:113-128. doi: 10.1016/j.molmet.2018.03.006. PMID: 29678421; PMCID: PMC6001387.
Castilla-Cortazar I, De Ita JR, García-Magariño M, Aguirre GA, Castorena-Torres F, Valdez-Garcia JE, Ortiz-Urbina J, de la Garza RG, Fraustro-Avila E, Rodríguez-Zambrano MA, Elizondo MI. A 42-Year-Old Woman with Untreated Growth Hormone Insensitivity, Diabetic Retinopathy, and Gene Sequencing Identifies a Variant of Laron Syndrome. Am J Case Rep. 2019; 20:689-696. doi: 10.12659/AJCR.913178. PMID: 31086127; PMCID: PMC6530522.
Lutski M, Zucker I, Zadik Z, Libruder C, Blumenfeld O, Shohat T, Laron Z. Prevalence of diabetes among children treated with growth hormone in Israel. Diabet Med. 2019; 36(10):1276-1281. doi: 10.1111/dme.13910. PMID: 30690790
Guevara-Aguirre J, Teran E, Lescano D, Guevara C, Guevara A, Saavedra J, Procel P, Wasserfall C, Gavilanes AWD. Assessing insulin sensitivity and resistance in syndromes of severe short stature. Growth Horm IGF Res. 2020; 53-54:101339. doi: 10.1016/j.ghir.2020.101339. PMID: 32763832.
Amaratunga SA, Tayeb TH, Dusatkova P, Pruhova S, Lebl J. Invaluable Role of Consanguinity in Providing Insight into Paediatric Endocrine Conditions: Lessons Learnt from Congenital Hyperinsulinism, Monogenic Diabetes, and Short Stature. Horm Res Paediatr. 2022;95(1):1-11. doi: 10.1159/000521210. Epub 2021 Nov 30. PMID: 34847552.
Sarfstein R, Nagaraj K, Parikh S, Levy C, Laron Z, Benayahu D, Werner H. Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action. Cells. 2022; 11(10):1627. doi: 10.3390/cells11101627. PMID: 35626664; PMCID: PMC9139319.
Murray PG, Clayton PE. Disorders of Growth Hormone in Childhood. 2022. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905205.
Yaron-Saminsky D, Nagaraj K, Sarfstein R, Laron Z, Pasmanik-Chor M, Werner H. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression. Int J Mol Sci. 2021;22(21):11861. doi: 10.3390/ijms222111861. PMID: 34769292; PMCID: PMC8584665.
Washburn RL, Hibler T, Thompson LA, Kaur G, Dufour JM. Therapeutic application of Sertoli cells for treatment of various diseases. Semin Cell Dev Biol. 2022;121:10-23. doi: 10.1016/j.semcdb.2021.04.007. PMID: 33910764.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Revista Científica Arbitrada Multidisciplinaria PENTACIENCIAS - ISSN 2806-5794.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
